Cargando…

Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease

BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. Several evidences prove the relationship between coronary artery disease and response t...

Descripción completa

Detalles Bibliográficos
Autores principales: Forood, Afsaneh, Malekpour-Afshar, Reza, Mahdavi, Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kerman University of Medical Sciences 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354217/
https://www.ncbi.nlm.nih.gov/pubmed/25984279
_version_ 1782360722121949184
author Forood, Afsaneh
Malekpour-Afshar, Reza
Mahdavi, Amin
author_facet Forood, Afsaneh
Malekpour-Afshar, Reza
Mahdavi, Amin
author_sort Forood, Afsaneh
collection PubMed
description BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. Several evidences prove the relationship between coronary artery disease and response to fibrinolytic therapy in patients with myocardial infarction (MI) with PAI-1 level. Opium addiction is one of the most important factors in causing MI and cardiovascular events. This is due to it causing imbalance between coagulation and anticoagulation factors in the blood. This study was designed and implemented to determine the levels of PAI-I in opium-addicted patients with coronary artery disease in comparison with non addicts. METHODS: In this case-control study, 160 patients with coronary heart disease (CHD), which was confirmed by angiography results, were enrolled. All of the patients had a medical history, their creatinine levels and lipid profile were evaluated, morphine urine test was performed, and after that a blood sample was taken to determine the levels of PAI-1. Thus, the 80 patients who had a positive morphine urine test result formed the case group, and the control group was constituted of the 80 patients with negative morphine test results. The two groups were matched. FINDINGS: Average level of PAI-1 in the control group was 2.4 ± 2.6 and in the case group was 8.8 ± 9.1 and it was statistically significant (P < 0.001). The frequency of two vessel disease was higher in opium addicted patients than non-addicted patients and this was statistically significant (P = 0.030). However, the frequency of single vessel and three vessel disease was the same in the two groups. The two groups had no differences in age, lipid profile, and creatinine level. Moreover, females are at a higher risk of high PAI-1 levels. CONCLUSION: PAI-1 levels in opium addicted patients with CHD are higher than other patients. In these patients, the risk of atherosclerosis and MI is higher than normal.
format Online
Article
Text
id pubmed-4354217
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Kerman University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-43542172015-05-15 Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease Forood, Afsaneh Malekpour-Afshar, Reza Mahdavi, Amin Addict Health Original Article BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) is a glycoprotein with inhibitory effects on the formation of plasmin from plasminogen by plasminogen activator. Thus, it prevents clot lysis in vessel walls. Several evidences prove the relationship between coronary artery disease and response to fibrinolytic therapy in patients with myocardial infarction (MI) with PAI-1 level. Opium addiction is one of the most important factors in causing MI and cardiovascular events. This is due to it causing imbalance between coagulation and anticoagulation factors in the blood. This study was designed and implemented to determine the levels of PAI-I in opium-addicted patients with coronary artery disease in comparison with non addicts. METHODS: In this case-control study, 160 patients with coronary heart disease (CHD), which was confirmed by angiography results, were enrolled. All of the patients had a medical history, their creatinine levels and lipid profile were evaluated, morphine urine test was performed, and after that a blood sample was taken to determine the levels of PAI-1. Thus, the 80 patients who had a positive morphine urine test result formed the case group, and the control group was constituted of the 80 patients with negative morphine test results. The two groups were matched. FINDINGS: Average level of PAI-1 in the control group was 2.4 ± 2.6 and in the case group was 8.8 ± 9.1 and it was statistically significant (P < 0.001). The frequency of two vessel disease was higher in opium addicted patients than non-addicted patients and this was statistically significant (P = 0.030). However, the frequency of single vessel and three vessel disease was the same in the two groups. The two groups had no differences in age, lipid profile, and creatinine level. Moreover, females are at a higher risk of high PAI-1 levels. CONCLUSION: PAI-1 levels in opium addicted patients with CHD are higher than other patients. In these patients, the risk of atherosclerosis and MI is higher than normal. Kerman University of Medical Sciences 2014 /pmc/articles/PMC4354217/ /pubmed/25984279 Text en © 2014 Kerman University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Forood, Afsaneh
Malekpour-Afshar, Reza
Mahdavi, Amin
Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease
title Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease
title_full Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease
title_fullStr Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease
title_full_unstemmed Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease
title_short Serum Level of Plasminogen Activator Inhibitor Type-1 in Addicted Patients with Coronary Artery Disease
title_sort serum level of plasminogen activator inhibitor type-1 in addicted patients with coronary artery disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354217/
https://www.ncbi.nlm.nih.gov/pubmed/25984279
work_keys_str_mv AT foroodafsaneh serumlevelofplasminogenactivatorinhibitortype1inaddictedpatientswithcoronaryarterydisease
AT malekpourafsharreza serumlevelofplasminogenactivatorinhibitortype1inaddictedpatientswithcoronaryarterydisease
AT mahdaviamin serumlevelofplasminogenactivatorinhibitortype1inaddictedpatientswithcoronaryarterydisease